Experiencia sobre el uso de pirfenidona en pacientes con fibrosis pulmonar idiopática en hospital de Puerto Montt

Abstract

 Background: Idiopathic Pulmonary Fibrosis (IPF) is a disease of unknown cause and high morta lity. Pirfenidone may reduce the decline in lung function and improve progression-free survival. Despite being approved for use in IPF, there is little data on its use in Chile, and at the Puerto Montt Hospital it was recently approved for a restricted number of patients. Objective: To study the clinical, functional and tolerance outcomes obtained with Pirfenidone in patients with IPF, seeking to increase the number of treated patients and/or incorporate nintedanib. Methods: Prospective descriptive study of 25 subjects diagnosed with IPF treated at the Puerto Montt Hospital in Sothern Chile between April 2022 and April 2023. Clinical, functional, and radiological information was recorded, along with reported adverse events and adherence to the medication. Results: Of 25 patients with IPF, 50% had dyspnea ≥ 2 on mMRC scale, 13 had a DLCO ≤ 50%, and 22% had a final SpO2 in the six minutes walk test ≤ 88%. Ten patients had an adverse reaction to the medication, but only one had to discontinue it, the other patients controlled the symptoms by reducing the dose. At one year of follow-up, 74% maintained treatment, the main cause of discontinuation was the progression of the disease. 29% had a decline in FVC ≥ 5% in one year. Conclusions: In our study, it was possible to treat patients with deteriorated lung function, achieving good adherence to treatment, stability of lung function, and reduction of symptoms, even using reduced doses of Pirfenidone.